Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 1/2 1

Status

Completed 4Unknown 1Active not recruiting 1

Sponsor Class

OTHER 4NIH 2

Study Type

Interventional 6

Sponsor

Cancer Type

Plasma cell 6Classical hematology 1

Conditions

Multiple Myeloma 6Neoplasm Metastasis 4Carcinoma 4Breast Neoplasms 4Neoplasms 3Melanoma 3Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Glioma 2Fallopian Tube Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Unspecified Childhood Solid Tumor, Protocol Specific 1Skin Neoplasms 1Sarcoma, Synovial 1Sarcoma 1Rhabdoid Tumor 1Recurrence 1Ras-mutated Metastatic Colorectal Cancer 1Prostatic Neoplasms 1Osteosarcoma 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive 1Medulloblastoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Glioblastoma 1Fibrosarcoma 1Diffuse Intrinsic Pontine Glioma 1

Interventions

Dexamethasone 808Bortezomib 446Lenalidomide 430Cyclophosphamide 336Melphalan 250Calcium Dobesilate 236daratumumab 217pomalidomide 201carfilzomib 181fludarabine phosphate 131Thalidomide 121fludarabine 118Peripheral Blood Stem Cell Transplantation 117Filgrastim 111ixazomib 85Mycophenolic Acid 85Granulocyte Colony-Stimulating Factor 84Busulfan 83Whole-Body Irradiation 80Tacrolimus 75dexamethasone acetate 74Cyclosporine 67Prednisone 64dexamethasone 21-phosphate 63isatuximab 62elotuzumab 60auricularum 57Antilymphocyte Serum 55belantamab mafodotin 54Etoposide 52

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Multiple Myeloma × reolysin × Clear all
NCT05514990 2026-05-13

Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial

University of Southern California

Phase 1/2 Active not recruiting
10 enrolled
Plasma cell

Multiple Myeloma

NCT02101944 2024-05-17

Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

National Cancer Institute (NCI)

Phase 1 Completed
12 enrolled
Classical hematologyPlasma cell

Anemia, Multiple Myeloma

NCT03605719 2023-10-06

Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma

Emory University

Phase 1 Completed
23 enrolled
Plasma cell

Multiple Myeloma

NCT02514382 2023-08-14

Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

University of Southern California

Phase 1 Completed
14 enrolled
Plasma cell

Multiple Myeloma

NCT03015922 2020-01-22

MUKeleven

University of Leeds

Phase 1 Unknown
4 enrolled
Plasma cell

Multiple Myeloma

NCT01533194 2015-04-15

Viral Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma

National Cancer Institute (NCI)

Phase 1 Completed
12 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡